APA (7th ed.) Citation

Krejczy, M., Harenberg, J., Hetjens, S., Obermann, K., Frölich, L., & Wehling, M. (2014). Comparison of cost-effectiveness of anticoagulation with dabigatran, rivaroxaban and apixaban in patients with non-valvular atrial fibrillation across countries. Journal of thrombosis and thrombolysis, 37(4), . https://doi.org/10.1007/s11239-013-0989-6

Chicago Style (17th ed.) Citation

Krejczy, Martin, Job Harenberg, Svetlana Hetjens, Konrad Obermann, Lutz Frölich, and Martin Wehling. "Comparison of Cost-effectiveness of Anticoagulation with Dabigatran, Rivaroxaban and Apixaban in Patients with Non-valvular Atrial Fibrillation Across Countries." Journal of Thrombosis and Thrombolysis 37, no. 4 (2014). https://doi.org/10.1007/s11239-013-0989-6.

MLA (9th ed.) Citation

Krejczy, Martin, et al. "Comparison of Cost-effectiveness of Anticoagulation with Dabigatran, Rivaroxaban and Apixaban in Patients with Non-valvular Atrial Fibrillation Across Countries." Journal of Thrombosis and Thrombolysis, vol. 37, no. 4, 2014, https://doi.org/10.1007/s11239-013-0989-6.